Compare Davita Inc (DVA) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Northrop Grumman Corporation — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while Northrop Grumman Corporation trades at $575.43 (market cap $82.10B). The key difference: Northrop Grumman Corporation is far larger — about 7× Davita Inc's market cap, and Northrop Grumman Corporation pays a 1.63% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | NOC | |
|---|---|---|
Market Cap | $11.72B | $82.10B |
Sector | Health | Industrials |
52-Week High | $240.96 | $768.02 |
52-Week Low | $103.87 | $496.02 |
Enterprise Value | $24.44B | $96.08B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Northrop Grumman (NOC) trades at $571.58, up 0.68% on the day, with a bullish technical signal driven by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating EPS estimates with $7.68 actual versus $6.82 expected, and raised full-year guidance amid a record $105 billion backlog. Fundamentals show robust profitability with a 10.48% net income margin and 26.96% ROE, while valuation metrics like a P/E of 18.17 appear reasonable relative to growth.
Outlook remains positive given defense spending tailwinds and contract wins like the $7.6 billion Sentinel program, though margin pressures and high debt levels pose risks. Analysts are bullish with a $598.57 consensus target, implying ~5% upside from current levels, supported by 20 buy ratings versus 1 sell.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
